• Spruce Biosciences named Agnieszka “AJ” Jurecka vice president, medical affairs, as it prepares for a potential U.S. FDA decision on tralesinidase alfa.
• She most recently served as chief medical officer at a seed-stage gene therapy company developing CNS-directed therapies for lysosomal gene defects.
• Jurecka previously led rare-disease programs at CoA Therapeutics and Ultragenyx, with earlier medical affairs roles at Shire, Synageva, Aegerion, and BioMarin.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spruce Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606220800BIZWIRE_USPR_____20260622_BW751434) on June 22, 2026, and is solely responsible for the information contained therein.